Clinical Trials in Illinois

Showing 3861-3880 of 19,692 trials

Randomized Blinded Evaluation of the Effects of TENS and IFC Compared to a Sham Device and SOC in Patients With Non-Specific CLBP

NCT05972889

This is a prospective, sham-controlled, randomized, single-blinded, multi-center study comparing two different modes of the NexWave device, transcutaneous electrical nerve stimulation (TENS) and interferential current (IFC), with an identical non-functioning NexWave sham device or self-defined standard of care for improvement of pain intensity of non-specific CLBP.

Non-Specific Chronic Lower Back Pain

Zynex Medical, Inc.334 participantsStarted Nov 2023

Greenwood Village, Colorado, United States • Saint Augustine, Florida, United States • Atlanta, Georgia, United States +5 more locations

RECRUITINGPhase 344 miles

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

NCT06008093

The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS.

Carcinoma, Non-Small-Cell Lung

AstraZeneca280 participantsStarted Apr 2024

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Chandler, Arizona, United States +102 more locations

Randomized Blinded Evaluation of the Effects of TENS and IFC Compared to a Sham Device and SOC in Patients With Non-Specific CLBP

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Find Trials by Condition in Illinois

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Prophylactic Salpingectomy With Delayed Oophorectomy

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension

Phase 2b Study of GSK4532990 in Adults With NASH

A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia

Safety and Effectiveness Study of OR3O™ Dual Mobility System in THA

Evaluating the Association Between Changes in the Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer

Determining Optimal Treatment Intensity for Children With Language Impairment

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function

Pediatric Patients Aged 4 to 11 Years With APDS

Stryker's Surgeon iD Mandible Reconstruction Plates: A Retrospective Post Market Follow Up